(www.hermopharma.com) – Hermo Pharma has closed its Series A round of venture funding. The series was led by Aloitusrahasto Vera (Avera) Ltd. and the Helsinki University Funds. A number of private investors, including ex-Roche R&D head Jonathan Knowles, participated in this round of financing. Dr. Knowles has been a member of Board of Directors at Hermo Pharma since 2010. Hermo Pharma is currently running a Phase 2a clinical study in adult amblyopia and preparing to initiate a first-in-man trial in Parkinson’s disease. The Series A funding will significantly support the company’s efforts in completing these development stages.